Literature DB >> 28855157

H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations.

Bernhard Lehnertz1, Yu Wei Zhang1, Isabel Boivin1, Nadine Mayotte1, Elisa Tomellini1, Jalila Chagraoui1, Vincent-Philippe Lavallée1,2, Josée Hébert1,2,3,4, Guy Sauvageau1,2,3,4.   

Abstract

Neomorphic missense mutations affecting crucial lysine residues in histone H3 genes significantly contribute to a variety of solid cancers. Despite the high prevalence of H3K27M mutations in pediatric glioblastoma and their well-established impact on global histone H3 lysine 27 di- and trimethylation (H3K27me2/3), the relevance of these mutations has not been studied in acute myeloid leukemia (AML). Here, we report the first identification of H3K27M and H3K27I mutations in patients with AML. We find that these lesions are major determinants of reduced H3K27me2/3 in these patients and that they are associated with common aberrations in the RUNX1 gene. We demonstrate that H3K27I/M mutations are strong disease accelerators in a RUNX1-RUNX1T1 AML mouse model, suggesting that H3K27me2/3 has an important and selective leukemia-suppressive activity in this genetic context.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28855157     DOI: 10.1182/blood-2017-03-774653

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Solid tumours hijack the histone variant network.

Authors:  Flávia G Ghiraldini; Dan Filipescu; Emily Bernstein
Journal:  Nat Rev Cancer       Date:  2021-02-10       Impact factor: 60.716

Review 2.  Developmental origins and emerging therapeutic opportunities for childhood cancer.

Authors:  Mariella Filbin; Michelle Monje
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

Review 3.  Dissecting cell fate dynamics in pediatric glioblastoma through the lens of complex systems and cellular cybernetics.

Authors:  Abicumaran Uthamacumaran
Journal:  Biol Cybern       Date:  2022-06-09       Impact factor: 3.072

4.  Telomere dysfunction cooperates with epigenetic alterations to impair murine embryonic stem cell fate commitment.

Authors:  Aditi Qamra; Tsz Wai Chu; Mélanie Criqui; Monika Sharma; Julissa Tsao; Danielle A Henry; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Neil Winegarden; Mathieu Lupien; Lea Harrington
Journal:  Elife       Date:  2020-04-16       Impact factor: 8.140

Review 5.  Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer.

Authors:  Alexey A Soshnev; C David Allis; Ethel Cesarman; Ari M Melnick
Journal:  Cancer Res       Date:  2021-09-27       Impact factor: 13.312

Review 6.  Chromatin Bottlenecks in Cancer.

Authors:  Jay F Sarthy; Steven Henikoff; Kami Ahmad
Journal:  Trends Cancer       Date:  2019-02-26

7.  Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.

Authors:  Nicole A McNeer; John Philip; Heather Geiger; Rhonda E Ries; Vincent-Philippe Lavallée; Michael Walsh; Minita Shah; Kanika Arora; Anne-Katrin Emde; Nicolas Robine; Todd A Alonzo; E Anders Kolb; Alan S Gamis; Malcolm Smith; Daniela Se Gerhard; Jaime Guidry-Auvil; Soheil Meshinchi; Alex Kentsis
Journal:  Leukemia       Date:  2019-02-13       Impact factor: 11.528

8.  PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.

Authors:  Siddhant U Jain; Truman J Do; Peder J Lund; Andrew Q Rashoff; Katharine L Diehl; Marcin Cieslik; Andrea Bajic; Nikoleta Juretic; Shriya Deshmukh; Sriram Venneti; Tom W Muir; Benjamin A Garcia; Nada Jabado; Peter W Lewis
Journal:  Nat Commun       Date:  2019-05-13       Impact factor: 14.919

Review 9.  Histone H3 Mutations in Cancer.

Authors:  Yi Ching Esther Wan; Jiaxian Liu; Kui Ming Chan
Journal:  Curr Pharmacol Rep       Date:  2018-04-26

10.  Recurrent histone mutations in T-cell acute lymphoblastic leukaemia.

Authors:  Grace Collord; Inigo Martincorena; Matthew D Young; Letizia Foroni; Niccolo Bolli; Michael R Stratton; George S Vassiliou; Peter J Campbell; Sam Behjati
Journal:  Br J Haematol       Date:  2018-03-30       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.